Immunization News and Research

RSS

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination

The study, recently published in The Journal of the American Medical Association, deduced that previous SARS-CoV-2 infection is associated with a statistically significant reduced hazard of breakthrough infection among recipients of both the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines.

3 Nov 2021

Cross-reactive immunity against coronaviruses

Researchers review the heterologous immunity to coronaviruses and the extent of immune cross-reactivity against SARS-CoV-2.

3 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

Anti-inflammatory diets in COVID-19

A recent review of research published in the journal Diseases has shown that anti-inflammatory diets can be useful in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or reducing the severity of coronavirus disease 2019 (COVID-19).

3 Nov 2021

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

2 Nov 2021

CDC expands COVID-19 vaccine recommendations to about 28 million children aged 5-11 years

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine.

2 Nov 2021

Researchers explore whether salivary glands infected with SARS-CoV-2 can diminish long-term immunity

University of Utah Health scientists are leading an effort to determine if salivary glands infected with the virus that causes COVID-19 could diminish a person’s long-term immunity to the disease after being immunized or after recovering from the illness.

30 Oct 2021

Breakthrough COVID infections in Northeast Italy showing waning vaccine protection

Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.

28 Oct 2021

How long does natural or vaccine-induced immunity to COVID last?

Researchers present a comprehensive assessment on SARS-CoV-2 induced immunity.

28 Oct 2021

Third dose of Covid-19 vaccine benefits dialysis patients

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot.

28 Oct 2021

Malaria: An Interview with the World Health Organization

In this interview, we spoke to Dr. Akpaka Kalu, the World Health Organization's team leader for malaria in Africa, about the groundbreaking malaria vaccine rollout announcement.

28 Oct 2021

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Researchers investigated the neutralizing antibody response that different mRNA vaccines induce in both previously convalescent and SARS-CoV-2 naïve individuals.

28 Oct 2021

Two-dose SARS-CoV-2 vaccine effectiveness against infection and hospitalization in Canada

Authors from varying Canadian institutes report on two-dose vaccine effectiveness against infection and hospitalization.

28 Oct 2021

COVID vaccines deployed in US highly effective at reducing hospitalizations and deaths

Researchers in the United States have conducted a large-scale study showing that the two-dose regimen vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) appear to be highly effective and durable in reducing the risk of hospitalizations and deaths following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Oct 2021

SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection

Researchers at the University of Oxford have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) is associated with a lower risk of several sequelae among those who experience breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Oct 2021

Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19

Researchers emphasize that an effective vaccine should induce mucosal immunity and prevent the nasal entry of SARS-CoV-2.

27 Oct 2021

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination amongst healthcare workers

The heterologous ChAd/BNT combination confers better protection against SARS-CoV-2 infection than the homologous BNT/BNT combination in a real-world observational study of healthcare workers.

27 Oct 2021

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques.

26 Oct 2021

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat covid-19.

26 Oct 2021

Attitudes towards COVID-19 vaccination amongst essential workers

A new study has addressed these gaps in knowledge regarding the uptake of COVID-19 vaccines among essential workers.

26 Oct 2021

Immunization News and Research

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination

Cross-reactive immunity against coronaviruses

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Anti-inflammatory diets in COVID-19

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

CDC expands COVID-19 vaccine recommendations to about 28 million children aged 5-11 years

Researchers explore whether salivary glands infected with SARS-CoV-2 can diminish long-term immunity

Breakthrough COVID infections in Northeast Italy showing waning vaccine protection

How long does natural or vaccine-induced immunity to COVID last?

Third dose of Covid-19 vaccine benefits dialysis patients

Malaria: An Interview with the World Health Organization

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Two-dose SARS-CoV-2 vaccine effectiveness against infection and hospitalization in Canada

COVID vaccines deployed in US highly effective at reducing hospitalizations and deaths

SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection

Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination amongst healthcare workers

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

Attitudes towards COVID-19 vaccination amongst essential workers

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News